Pituitary-Tumor Endocrinopathies Pituitary adenomas account for about 15% of intracranial
tumors. Clinical manifestations of disease reflect the oversecretion of the involved hormone …

Adenohypophyseal tumors, which were recently renamed pituitary neuroendocrine tumors
(PitNET), are mostly benign, but may present various behaviors: invasive,“aggressive” and …

Objective To describe clinical and pathological characteristics and treatment outcomes in a
large cohort of aggressive pituitary tumours (APT)/pituitary carcinomas (PC). Design …

Substantial advances have been made recently in the pathobiology of pituitary tumors.
Similar to many other endocrine tumors, over the last few years we have recognized the role …

The classification of adenohypophysial neoplasms as “pituitary neuroendocrine
tumors”(PitNETs) was proposed in 2017 to reflect their characteristics as epithelial …

Aggressive pituitary tumors (APTs) and pituitary carcinomas (PCs) are heterogeneous with
regard to clinical presentation, proliferative markers, clinical course, and response to …

Abstract The 2017 World Health Organization (WHO) classification proposes to type and
subtype primary adenohypophyseal tumours according to their cell lineages with the aim to …

Non-functioning pituitary adenomas, recently alternatively termed pituitary neuroendocrine
tumours (NFpitNETs), are mostly benign neoplasms that are not associated with a hormonal …

Pituitary neuroendocrine tumor (PitNET) is one of the most common intracranial tumors with
variable recurrence rate. Currently, the recurrence prediction is unsatisfying and can be …

Pituitary adenomas are considered benign tumors, but approximately 10% of them can have
an aggressive behavior and more rarely (0.2%) can present metastasis, being classified as …